

PANCREAS
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 2nd, 2015

TIME: 11:15 - 12:30

CHAIRS: DR. STEVE GALLINGER, DR. DANIEL RENOUF

-
- 11:15 WELCOME AND INTRODUCTION/MEMBERSHIP UPDATE
DR. S. GALLINGER/DR. D. RENOUF
- 11:15 OPEN TRIALS
- PA.6 (ACCORD 24):** RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA
DR. A. WEI / DR. J. BIAGI
- 11:25 TRIALS/CONCEPTS IN DEVELOPMENT
- ALLIANCE 021101:** NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE_ARM PILOT STUDY
DR. A. WEI/DR. S. GALLINGER
- SWOG S1505:** FOLFIRINOX *VERSUS* GEMCITABINE/NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II STUDY
DR. D. RENOUF
- PHASE II TRIAL OF FOLFIRINOX *VERSUS* GEMCITABINE/NAB-PACLITAXEL IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRCA WT PANCREAS CANCER
DR. D. RENOUF
- 11:55 INTERGROUP TASK FORCE UPDATE
DR. D. RENOUF
- 12:05 DISCUSSION – NON-TRIAL ISSUES
DR. S. GALLINGER
- CLOSING REMARKS